Go Pro
NASDAQ:TRVN

Trevena (TRVN) Stock Price, News & Analysis

Trevena logo
$0.01 0.00 (0.00%)
As of 09/22/2026

About Trevena Stock (NASDAQ:TRVN)

Advanced

Key Stats

Today's Range
$0.0112
$0.0112
50-Day Range
N/A
52-Week Range
$0.00
$1.50
Volume
19 shs
Average Volume
726 shs
Market Capitalization
$10.74 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Trevena, Inc. is a biopharmaceutical company focused on developing medicines that target G protein-coupled receptors (GPCRs), a class of proteins involved in pain, neurological conditions and other diseases. The company was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Trevena’s best-known product is OLINVYK (oliceridine) injection, an intravenous opioid analgesic approved by the U.S. Food and Drug Administration in 2020 for the management of acute pain severe enough to require an intravenous opioid analgesic in adults. OLINVYK was designed as a selective mu-opioid receptor agonist and was developed to provide pain relief while addressing certain limitations associated with traditional opioid therapies.

The company has also conducted research on additional therapies for pain and central nervous system disorders, including investigational oral and non-opioid treatments. Trevena’s primary commercial and regulatory activities have been focused on the United States, while its development programs and partnerships have supported efforts to expand the potential reach of its drug candidates. Because the company’s operations and product-development activities have changed over time, investors should consult its latest public filings for current information about its leadership, pipeline and commercial status.

AI Generated. May Contain Errors.

Receive TRVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevena and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TRVN Stock News Headlines

Trevena Inc.
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
Trevena, Inc. (TRVN) - Yahoo Finance
See More Headlines

TRVN Stock Analysis - Frequently Asked Questions

Trevena's stock was trading at $0.0120 at the start of the year. Since then, TRVN stock has decreased by 6.7% and is now trading at $0.0112.

Trevena, Inc. (NASDAQ:TRVN) issued its quarterly earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($9.25) by $9.02. The biopharmaceutical company had revenue of $0.33 million for the quarter.

Trevena's stock reverse split before market open on Tuesday, August 13th 2024.The 1-25 reverse split was announced on Thursday, August 8th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Shares of TRVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Trevena investors own include Novavax (NVAX), Conatus Pharmaceuticals (CNAT), Sorrento Therapeutics (SRNE), NIO (NIO), TherapeuticsMD (TXMD), SCYNEXIS (SCYX).

Company Calendar

Last Earnings
8/08/2024
Today
9/23/2026
Next Earnings (Estimated)
11/05/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:TRVN
CIK
1429560
Fax
N/A
Employees
23
Year Founded
2008

Profitability

EPS (Trailing Twelve Months)
($47.04)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$40.29 million
Net Margins
N/A
Pretax Margin
-6,222.30%
Return on Equity
N/A
Return on Assets
-119.55%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.42
Quick Ratio
2.42

Sales & Book Value

Annual Sales
$443 thousand
Price / Sales
0.02
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($11.07) per share
Price / Book
0.00

Miscellaneous

Outstanding Shares
959,000
Free Float
841,000
Market Cap
$10.74 thousand
Optionable
No Data
Beta
-0.55

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:TRVN) was last updated on 9/23/2026 by MarketBeat.com Staff.
From Our Partners